Doctor-patient discussions neglect potential harms of lung cancer screening, study finds

August 13, 2018, UNC Lineberger Comprehensive Cancer Center
Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia

Although national guidelines advise doctors to discuss the benefits and harms of lung cancer screening with high-risk patients because of a high rate of false positives and other factors, those conversations aren't happening the way they should be, according to a study by researchers from the University of North Carolina Lineberger Comprehensive Cancer Center.

Lung cancer is recommended for high-risk current and former smokers, but because of the potential harms of screening, the U.S. Preventive Services Task Force and other organizations advise physicians and patients to discuss the potential risks and benefits of screening. UNC Lineberger researchers report in JAMA Internal Medicine that their analysis of 14 audio-recorded office visit discussions between doctors and patients found the quality of the conversation about was "poor" and discussion of the potential harms of screening was "virtually nonexistent." In addition, the doctors spent less than a minute, on average, discussing the issue.

"We're not taking a side as to whether cancer screening is good or bad, but there seems to be a consensus that we should be sharing these complex decisions with patients," said UNC Lineberger's Daniel Reuland, MD, MPH, director of UNC Lineberger's Carolina Cancer Screening Initiative and the study's senior author. "Our fly-on-the-wall sample from real-world practice shows us that's not happening."

Lung cancer is the leading cause of cancer death in the United States. The American Cancer Society estimates that more than 234,000 people will be diagnosed with lung cancer in the country this year and the disease will cause more than 154,000 deaths. The National Lung Screening Trial (NLST) found that detecting lung cancer in its earliest stages can reduce a person's risk of dying from the disease.

Since 2013, the U.S. Preventative Services Task Force has recommended annual lung cancer screening using low-dose computed tomography (CT) in adults aged 55 to 80 years who have smoked a minimum of 30 pack-years, which amounts to 20 cigarettes per day each year for 30 years, and who are still smoking or have only quit in the last 15 years.

The NLST showed that with lung cancer screening using low-dose spiral CT scan, there were about 20 percent fewer lung cancer deaths among people at very high risk from the disease compared with screening with chest X-ray. However, the trial also identified potential harms of screening, including false positive findings. More than 95 percent of lung nodules found on screening CT scans are not cancer. Because of this, many patients with abnormal results will need follow-up procedures that can be invasive, and ultimately do not find cancer. The trial also showed that screening leads to the diagnosis of cancers that, left untreated, would not have affected the patient during his or her lifetime—a phenomenon known as over diagnosis, according to a study published in JAMA Internal Medicine, led by Edward F. Patz Jr, MD.

"A lot of people undergo surveillance, additional scanning, and some people undergo invasive procedures who don't have lung ," said Reuland, who is also a professor at the UNC School of Medicine in the Division of General Medicine and Clinical Epidemiology. "The problem is weighing a small chance of benefit in the form of prolonged life versus a larger chance that a given patient will incur some kind of physical or psychological harm, plus out-of-pocket costs. It's important to talk about those potential harms and benefits with patients when deciding about screening."

These discussions are recommended and, in some case, required by national guidelines. Before it will pay for a screening procedure, the U.S. Centers for Medicare and Medicaid Services requires a doctor-patient discussion about the benefits and harms, issues of over-diagnosis, the false-positive rate, and risk of total radiation exposure from the test. The USPSTF advises the decision to screen should be made after a "thorough discussion of the possible benefits, limitations and the known and uncertain harms."

To see if discussions were happening, Reuland and his colleagues analyzed transcripts of 14 screening discussions they identified in a large database of conversations between doctors and patients provided by the private company Verilogue. The conversations were found by electronically searching 5,300 recorded interactions between physicians and age-eligible patients. Of 137 conversations that met keyword criteria, only 14 specifically addressed screening. The researchers found that the conversations were brief and one-sided, and none of the doctors mentioned the potential harms of screening. No doctor explained false positive test results or the possible need for additional imaging or invasive diagnostic procedures.

"Although the sample was small, the results were stark and confirmed what we thought we would find," Reuland said. "Shared decision making isn't happening in practice as well as it should or as well as we'd like to think it is. There's a big gap between what guidelines say and what actually happens."

Reuland said better systems and infrastructure are needed to ensure these conversations happen the way they should.

"We need to design systems that make patient care and medical decisions more informed and shared, and we need to take that responsibility seriously," he said. "Issuing guidelines and payer-based regulations saying we should be doing shared decision-making is fine, but it isn't enough. Among other things, we need more efficient and reliable ways of getting involved in these decisions.

Finding better ways of having clinical support staff help with the delivery of patient education, particularly using educational tools known as decision aids, will be important," Reuland added. "Patient support for making complex decisions probably shouldn't rely only on doctors with limited time for each patient visit and a lengthy visit agenda."

Explore further: Prediction tool helps tailor lung cancer screening to patients

Related Stories

Prediction tool helps tailor lung cancer screening to patients

May 30, 2018
(HealthDay)—Personalizing the harm-benefit assessment of low-dose computed tomography (LDCT) screening for lung cancer can inform patient-centered screening decisions, according to a study published online May 29 in the ...

Making individualized choices about breast cancer screening

May 1, 2018
In a JAMA Insights article, published on May 1 by JAMA, co-authors Keating and Pace summarize the current state of breast cancer screening. The authors note, that despite the fact that the United States Preventive Services ...

Risk-based lung cancer screening may save more lives than current USPSTF guidelines

January 2, 2018
Lung cancer screening based on individual risk has the potential to save more lives than current recommendations by the U.S. Preventive Services Task Force (USPSTF). The findings are published in Annals of Internal Medicine.

Lung cancer decision aids are helpful for patients

September 30, 2016
(HealthDay)—Outpatients find lung cancer screening decision aids helpful, according to a study published online Sept. 21 in the Annals of the American Thoracic Society.

Risk-based CT screening may reduce deaths from lung cancer

January 1, 2018
Compared to National Lung Screening Trial criteria, targeting screening those at highest risk from lung cancer mortality using a risk prediction tool may improve efficiency in terms of greater reduction in mortality from ...

Many family physicians have inaccurate knowledge about lung cancer screening

June 13, 2016
Although clinical trials have shown that lung cancer screening using low-dose computed tomography (LDCT) can detect lung cancers early and reduce lung cancer mortality, less than half of family physicians in a recent survey ...

Recommended for you

Repurposing FDA-approved drugs can help fight back breast cancer

November 16, 2018
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in ...

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds

November 15, 2018
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

Researchers identify a mechanism that fuels cancer cells' growth

November 14, 2018
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified sodium glucose transporter 2, or SGLT2, as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes ...

A new approach to detecting cancer earlier from blood tests: study

November 14, 2018
Cancer scientists led by principal investigator Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have combined "liquid biopsy", epigenetic alterations and machine learning to develop a blood test to detect and classify ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.